Austar Lifesciences Limited board of directors announced that the group is expected to record a substantial reduction of not less than 60% in consolidated profits attributable to the shareholders of the company for the six months ending June 30, 2015, as compared with the corresponding period in 2014, mainly attributable to: delay in recognition of revenue due to subsequent modification of users requirements for projects undertaken by the Group during the past few months; and decrease in gross profit margin for certain projects undertaken by the Group.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.86 HKD | +3.61% | +17.81% | -44.87% |
Mar. 26 | Austar Lifesciences Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Jan. 22 | Austar Lifesciences to Swing to Loss; Shares Drop | MT |
1st Jan change | Capi. | |
---|---|---|
-44.87% | 54.45M | |
-4.84% | 182B | |
+0.56% | 110B | |
-3.35% | 68.11B | |
+2.39% | 50.53B | |
+9.36% | 44.8B | |
+2.84% | 40.7B | |
+24.51% | 32.25B | |
+3.43% | 26.53B | |
+15.25% | 25.02B |
- Stock Market
- Equities
- 6118 Stock
- News Austar Lifesciences Limited
- Austar Lifesciences Limited Provides Earnings Guidance for the Six Months Ending June 30, 2015